{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:24:10Z","timestamp":1794453850062,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CellAvita Pesquisas Cientificas LTD","award":["01"],"award-info":[{"award-number":["01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Huntington\u2019s disease (HD) is a progressive neurodegenerative disorder with no approved disease-modifying therapies. Human dental pulp stem cells (hDPSCs) offer potential therapeutic benefits due to their neurogenic, neurotrophic, and immunomodulatory properties. This prospective, open-label, single-centre, first-in-human clinical trial evaluated the safety, tolerability, and preliminary efficacy of intravenous hDPSC in patients with HD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Six male patients with HD received intravenous infusions of hDPSCs in two dosage cohorts: three patients received 1 million cells\/kg, and three received 2 million cells\/kg. The treatment protocol consisted of cycles of three infusions at monthly intervals followed by subsequent administration cycles every six months, as per a protocol amendment based on the initial favourable safety outcomes. The total number of infusions ranged from 4 to 26 over the five years. During the first year, all patients underwent intensive multiparametric monitoring in an intensive care unit (ICU) for 48 h after each infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No adverse events occurred during the 48-h ICU monitoring or within 15 days post-infusion. Of 41 treatment-emergent adverse events (TEAEs) reported during follow-up, 35 were judged unrelated to the hDPSCs, mainly reflecting disease progression or incidental findings. Six treatment-emergent adverse events (TEAEs) were considered treatment-related, involving transient changes in hair pigmentation or regrowth. One patient discontinued due to a serious adverse event\u2014lung cancer arising from a pre-existing pulmonary nodule identified at enrolment. Genetic analysis of the excised tumour showed no evidence of investigational product engraftment, supporting its non-tumorigenic nature. The same patient experienced a severe depressive episode lasting approximately 93 days; the relationship to treatment was considered uncertain. Minor, clinically insignificant fluctuations in CD4\/CD8 lymphocyte counts and cytokine levels were observed. Preliminary efficacy analyses indicated potential stabilisation of disease progression, particularly in the Unified Huntington\u2019s Disease Rating Scale (UHDRS), Total Motor Score (TMS) and Total Functional Capacity (TFC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>hDPSCs infusions were well tolerated and exhibited a favourable safety profile, even with prolonged exposure and follow-up. These findings support the continued clinical development and warrant further investigation in more extensive trials to assess therapeutic efficacy in Huntington\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      This study was registered on April 4, 2016, at ClinicalTrials.gov (identifier: NCT02728115;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02728115\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT02728115<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-025-04703-w","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:19:57Z","timestamp":1762251597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A phase I, open-label study of intravenous human dental pulp stem cells (NestaCell\u00ae) at two dose levels in patients with Huntington\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Joyce Macedo Sanches","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane Valverde","family":"Wenceslau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Hideki","family":"Ynoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4433-7580","authenticated-orcid":false,"given":"Irina","family":"Kerkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"12","key":"4703_CR1","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/ar.22808","volume":"296","author":"PV de Souza","year":"2013","unstructured":"de Souza PV, Alves FB, Costa Ayub CL, de Miranda Soares MA, Gomes JR. Human immature dental pulp stem cells (hIDPSCs), their application to cell therapy and bioengineering: an analysis by systematic revision of the last decade of literature. Anat Rec (Hoboken). 2013;296(12):1923\u20138.","journal-title":"Anat Rec (Hoboken)"},{"issue":"7","key":"4703_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jdent.2014.02.018","volume":"42","author":"M La Noce","year":"2014","unstructured":"La Noce M, Paino F, Spina A, Naddeo P, Montella R, Desiderio V, et al. Dental pulp stem cells: state of the art and suggestions for a true translation of research into therapy. J Dent. 2014;42(7):761\u20138.","journal-title":"J Dent"},{"issue":"20","key":"4703_CR3","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1016\/j.biomaterials.2006.02.009","volume":"27","author":"Y Yamada","year":"2006","unstructured":"Yamada Y, Fujimoto A, Ito A, Yoshimi R, Ueda M. Cluster analysis and gene expression profiles: a cDNA microarray system-based comparison between human dental pulp stem cells (hDPSCs) and human mesenchymal stem cells (hMSCs) for tissue engineering cell therapy. Biomaterials. 2006;27(20):3766\u201381.","journal-title":"Biomaterials"},{"issue":"11","key":"4703_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jnr.23250","volume":"91","author":"F Young","year":"2013","unstructured":"Young F, Sloan A, Song B. Dental pulp stem cells and their potential roles in central nervous system regeneration and repair. J Neurosci Res. 2013;91(11):1383\u201393.","journal-title":"J Neurosci Res"},{"key":"4703_CR5","doi-asserted-by":"publisher","first-page":"3516574","DOI":"10.1155\/2016\/3516574","volume":"2016","author":"H Ren","year":"2016","unstructured":"Ren H, Sang Y, Zhang F, Liu Z, Qi N, Chen Y. Comparative analysis of human mesenchymal stem cells from umbilical cord, dental pulp, and menstrual blood as sources for cell therapy. Stem Cells Int. 2016;2016:3516574.","journal-title":"Stem Cells Int"},{"issue":"1","key":"4703_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/stem.2398","volume":"35","author":"B Mead","year":"2017","unstructured":"Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Concise review: dental pulp stem cells: a novel cell therapy for retinal and central nervous system repair. Stem Cells. 2017;35(1):61\u20137.","journal-title":"Stem Cells"},{"key":"4703_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/5584_2017_71","volume":"1083","author":"I Mortada","year":"2018","unstructured":"Mortada I, Mortada R, Al BM. Dental pulp stem cells and neurogenesis. Adv Exp Med Biol. 2018;1083:63\u201375.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"4703_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/jnr.24122","volume":"96","author":"I Mortada","year":"2018","unstructured":"Mortada I, Mortada R, Al Bazzal M. Dental pulp stem cells and the management of neurological diseases: an update. J Neurosci Res. 2018;96(2):265\u201372.","journal-title":"J Neurosci Res"},{"issue":"5","key":"4703_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/1747493016641111","volume":"11","author":"A Nagpal","year":"2016","unstructured":"Nagpal A, Kremer KL, Hamilton-Bruce MA, Kaidonis X, Milton AG, Levi C, et al. TOOTH (The Open study Of dental pulp stem cell Therapy in Humans): Study protocol for evaluating safety and feasibility of autologous human adult dental pulp stem cell therapy in patients with chronic disability after stroke. Int J Stroke. 2016;11(5):575\u201385.","journal-title":"Int J Stroke"},{"issue":"1","key":"4703_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/scrt419","volume":"5","author":"KM Ellis","year":"2014","unstructured":"Ellis KM, O\u2019Carroll DC, Lewis MD, Rychkov GY, Koblar SA. Neurogenic potential of dental pulp stem cells isolated from murine incisors. Stem Cell Res Ther. 2014;5(1):30.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4703_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13287-025-04134-7","volume":"16","author":"B Pardo-Rodr\u00edguez","year":"2025","unstructured":"Pardo-Rodr\u00edguez B, Baraibar AM, Manero-Roig I, Luzuriaga J, Salvador-Moya J, Polo Y, et al. Functional differentiation of human dental pulp stem cells into neuron-like cells exhibiting electrophysiological activity. Stem Cell Res Ther. 2025;16(1):10.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"4703_CR12","first-page":"319","volume":"79","author":"Y Xu","year":"2019","unstructured":"Xu Y, Chen M, Zhang T, Ma Y, Chen X, Zhou P, et al. Spinal cord regeneration using dental stem cell-based therapies. Acta Neurobiol Exp (Wars). 2019;79(4):319\u201327.","journal-title":"Acta Neurobiol Exp (Wars)"},{"issue":"1","key":"4703_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13287-025-04244-2","volume":"16","author":"K Wang","year":"2025","unstructured":"Wang K, Liu X, Jiang X, Chen S, Wang H, Wang Z, et al. Human dental pulp stem cells for spinal cord injury. Stem Cell Res Ther. 2025;16(1):123.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4703_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1871527320666210311122921","volume":"21","author":"Y Sharma","year":"2022","unstructured":"Sharma Y, Shobha K, Sundeep M, Pinnelli VB, Parveen S, Dhanushkodi A. Neural basis of dental pulp stem cells and its potential application in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets. 2022;21(1):62\u201376.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"4703_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13287-020-01957-4","volume":"12","author":"Z Xiao","year":"2021","unstructured":"Xiao Z, Lei T, Liu Y, Yang Y, Bi W, Du H. The potential therapy with dental tissue-derived mesenchymal stem cells in Parkinson\u2019s disease. Stem Cell Res Ther. 2021;12(1):5.","journal-title":"Stem Cell Res Ther"},{"key":"4703_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2019.111727","volume":"203","author":"HA Alsaeedi","year":"2020","unstructured":"Alsaeedi HA, Lam C, Koh AE, Teh SW, Mok PL, Higuchi A, et al. Looking into dental pulp stem cells in the therapy of photoreceptors and retinal degenerative disorders. J Photochem Photobiol B. 2020;203:111727.","journal-title":"J Photochem Photobiol B"},{"issue":"9","key":"4703_CR17","first-page":"3546","volume":"25","author":"D Correa Maldonado","year":"2021","unstructured":"Correa Maldonado D, Nicoliche T, Faber J, Kerkis I, Martinez Saez D, Tetsuo Sasaki R, et al. Intra-articular human deciduous dental pulp stem cell administration vs. pharmacological therapy in experimental osteoarthritis rat model. Eur Rev Med Pharmacol Sci. 2021;25(9):3546\u201356.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"4703_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13287-021-02353-2","volume":"12","author":"PL Li","year":"2021","unstructured":"Li PL, Wang YX, Zhao ZD, Li ZL, Liang JW, Wang Q, et al. Clinical-grade human dental pulp stem cells suppressed the activation of osteoarthritic macrophages and attenuated cartilaginous damage in a rabbit osteoarthritis model. Stem Cell Res Ther. 2021;12(1):260.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4703_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13287-017-0621-3","volume":"8","author":"E Mart\u00ednez-Sarr\u00e0","year":"2017","unstructured":"Mart\u00ednez-Sarr\u00e0 E, Montori S, Gil-Recio C, N\u00fa\u00f1ez-Toldr\u00e0 R, Costamagna D, Rotini A, et al. Human dental pulp pluripotent-like stem cells promote wound healing and muscle regeneration. Stem Cell Res Ther. 2017;8(1):175.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4703_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13287-023-03447-9","volume":"14","author":"F Agriesti","year":"2023","unstructured":"Agriesti F, Landini F, Tamma M, Pacelli C, Mazzoccoli C, Calice G, et al. Bioenergetic profile and redox tone modulate in vitro osteogenesis of human dental pulp stem cells: new perspectives for bone regeneration and repair. Stem Cell Res Ther. 2023;14(1):215.","journal-title":"Stem Cell Res Ther"},{"key":"4703_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073546","author":"J Luzuriaga","year":"2021","unstructured":"Luzuriaga J, Polo Y, Pastor-Alonso O, Pardo-Rodr\u00edguez B, Larra\u00f1aga A, Unda F, et al. Advances and perspectives in dental pulp stem cell based neuroregeneration therapies. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22073546.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4703_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jcyt.2017.12.011","volume":"20","author":"E Anitua","year":"2018","unstructured":"Anitua E, Troya M, Zalduendo M. Progress in the use of dental pulp stem cells in regenerative medicine. Cytotherapy. 2018;20(4):479\u201398.","journal-title":"Cytotherapy"},{"key":"4703_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222112018","author":"JK Bar","year":"2021","unstructured":"Bar JK, Lis-Nawara A, Grelewski PG. Dental pulp stem cell-derived secretome and its regenerative potential. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222112018.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4703_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cbf.3723","volume":"40","author":"A Kumar","year":"2022","unstructured":"Kumar A, Mahajan A, Kumari P, Singh J, Raik S, Saha L, et al. Dental pulp stem cell secretome ameliorates d-galactose induced accelerated aging in rat model. Cell Biochem Funct. 2022;40(5):535\u201345.","journal-title":"Cell Biochem Funct"},{"key":"4703_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/0963689720952089","volume":"29","author":"M Zayed","year":"2020","unstructured":"Zayed M, Iohara K. Immunomodulation and regeneration properties of dental pulp stem cells: a potential therapy to treat Coronavirus disease 2019. Cell Transplant. 2020;29:963689720952089.","journal-title":"Cell Transplant"},{"key":"4703_CR26","doi-asserted-by":"crossref","unstructured":"Kumar A, Raik S, Sharma P, Rattan V, Bhattacharyya S. Primary culture of dental pulp stem cells. J Vis Exp. 2023(195).","DOI":"10.3791\/65223"},{"issue":"10","key":"4703_CR27","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.joen.2022.06.013","volume":"48","author":"S Nel","year":"2022","unstructured":"Nel S, Durandt C, Murdoch C, Pepper MS. Determinants of dental pulp stem cell heterogeneity. J Endod. 2022;48(10):1232\u201340.","journal-title":"J Endod"},{"issue":"9s","key":"4703_CR28","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.joen.2020.06.027","volume":"46","author":"B Sui","year":"2020","unstructured":"Sui B, Wu D, Xiang L, Fu Y, Kou X, Shi S. Dental pulp stem cells: from discovery to clinical application. J Endod. 2020;46(9s):S46-s55.","journal-title":"J Endod"},{"issue":"1","key":"4703_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.17311\/pharmacologia.2023.72.95","volume":"14","author":"RP Araldi","year":"2023","unstructured":"Araldi RP, Viana M, Colloza-Gama GA, Dias-Pinto JR, Ankol L, Wenceslau CV, et al. Unique transcriptional signatures observed in stem cells from the dental pulp of deciduous teeth produced on a large scale. Pharmacologia. 2023;14(1):72\u201395.","journal-title":"Pharmacologia"},{"key":"4703_CR30","doi-asserted-by":"crossref","unstructured":"Kerkis I, Valverde Wenceslau C, Pinheiro Araldi R. Stem cells from dental pulp of deciduous teeth: twenty years of experience. In: Al-Anazi KA, editor. Recent update on mesenchymal stem cells. Rijeka: IntechOpen; 2024.","DOI":"10.5772\/intechopen.1003850"},{"key":"4703_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells11101664","author":"CV Wenceslau","year":"2022","unstructured":"Wenceslau CV, de Souza DM, Mambelli-Lisboa NC, Ynoue LH, Araldi RP, da Silva JM, et al. Restoration of BDNF, DARPP32, and D2R expression following intravenous infusion of human immature dental pulp stem cells in Huntington\u2019s disease 3-NP rat model. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11101664.","journal-title":"Cells"},{"key":"4703_CR32","unstructured":"Gamarra L, Cintra L, G\u00e1rate AP. Relat\u00f3rio Final do Estudo de Biodistribui\u00e7\u00e3o do Produto NestaCell\u00ae. Centro de Experimenta\u00e7\u00e3o e Treinamento em Cirurgia (CETEC) do Instituto Israelita de Ensino e Pesquisa Hospital Albert Einstein; 2022."},{"key":"4703_CR33","unstructured":"RELAT\u00d3RIO FINAL DO ESTUDO DE TOXICIDADE DO PRODUTO NESTACELL\u00ae. Instituto Israelita de Ensino e Pesquisa Hospital Albert Einstein; 2022 21 de outubro de 2022. Report No.: Final."},{"key":"4703_CR34","unstructured":"Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products, FDA-2013-D-0576 (2015)."},{"issue":"3\u20134","key":"4703_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000099617","volume":"184","author":"I Kerkis","year":"2006","unstructured":"Kerkis I, Kerkis A, Dozortsev D, Stukart-Parsons GC, Gomes Massironi SM, Pereira LV, et al. Isolation and characterization of a population of immature dental pulp stem cells expressing OCT-4 and other embryonic stem cell markers. Cells Tissues Organs. 2006;184(3\u20134):105\u201316.","journal-title":"Cells Tissues Organs"},{"issue":"6","key":"4703_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039885","volume":"7","author":"NF Lizier","year":"2012","unstructured":"Lizier NF, Kerkis A, Gomes CM, Hebling J, Oliveira CF, Caplan AI, et al. Scaling-up of dental pulp stem cells isolated from multiple niches. PLoS ONE. 2012;7(6):e39885.","journal-title":"PLoS ONE"},{"issue":"4","key":"4703_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"issue":"1","key":"4703_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13287-025-04557-2","volume":"16","author":"JMS Fernandes","year":"2025","unstructured":"Fernandes JMS, Pagani E, Wenceslau CV, Ynoue LH, Ferrara L, Kerkis I. Phase II trial of intravenous human dental pulp stem cell therapy for Huntington\u2019s disease: a randomized, double-blind, placebo-controlled study. Stem Cell Res Ther. 2025;16(1):432\u201344.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4703_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000523896","volume":"15","author":"JM da Silva","year":"2022","unstructured":"da Silva JM, Araldi RP, Colozza-Gama GA, Pagani E, Sid A, Valverde CW, et al. Human immature dental pulp stem cells did not graft into a preexisting human lung adenocarcinoma. Case Rep Oncol. 2022;15(1):413\u201322.","journal-title":"Case Rep Oncol"},{"key":"4703_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.reth.2022.07.003","volume":"21","author":"A Alanazi","year":"2022","unstructured":"Alanazi A, Alassiri M, Jawdat D, Almalik Y. Mesenchymal stem cell therapy: a review of clinical trials for multiple sclerosis. Regen Ther. 2022;21:201\u20139.","journal-title":"Regen Ther"},{"key":"4703_CR41","doi-asserted-by":"crossref","unstructured":"De la Rosa-Ruiz MDP, Alvarez-Perez MA, Cortes-Morales VA, Monroy-Garcia A, Mayani H, Fragoso-Gonzalez G, et al. Mesenchymal stem\/stromal cells derived from dental tissues: a comparative in vitro evaluation of their immunoregulatory properties against T cells. Cells. 2019;8(12).","DOI":"10.3390\/cells8121491"},{"key":"4703_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176996","volume":"983","author":"W Ji","year":"2024","unstructured":"Ji W, Sun L, Wang D, Zhu W. Mesenchymal stem cells alleviate inflammatory responses through regulation of T-cell subsets. Eur J Pharmacol. 2024;983:176996.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"4703_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098050","volume":"9","author":"S Silva Fde","year":"2014","unstructured":"Silva Fde S, Ramos RN, de Almeida DC, Bassi EJ, Gonzales RP, Miyagi SP, et al. Mesenchymal stem cells derived from human exfoliated deciduous teeth (SHEDs) induce immune modulatory profile in monocyte-derived dendritic cells. PLoS ONE. 2014;9(5):e98050.","journal-title":"PLoS ONE"},{"issue":"6","key":"4703_CR44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824\u201333.","journal-title":"Cell Stem Cell"},{"issue":"8","key":"4703_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","volume":"14","author":"Y Shi","year":"2018","unstructured":"Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493\u2013507.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4703_CR46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2249.2010.04256.x","volume":"162","author":"MJ Crop","year":"2010","unstructured":"Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Pescatori M, Stubbs AP, et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol. 2010;162(3):474\u201386.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"4703_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010088","volume":"5","author":"RS Waterman","year":"2010","unstructured":"Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE. 2010;5(4):e10088.","journal-title":"PLoS ONE"},{"issue":"4","key":"4703_CR48","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.stem.2013.09.006","volume":"13","author":"ME Bernardo","year":"2013","unstructured":"Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392\u2013402.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"4703_CR49","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/leu.2011.108","volume":"25","author":"M Krampera","year":"2011","unstructured":"Krampera M. Mesenchymal stromal cell \u201clicensing\u201d: a multistep process. Leukemia. 2011;25(9):1408\u201314.","journal-title":"Leukemia"},{"issue":"8","key":"4703_CR50","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med. 2008;205(8):1869\u201377.","journal-title":"J Exp Med"},{"issue":"3","key":"4703_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nri3158","volume":"12","author":"HT Maecker","year":"2012","unstructured":"Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the human immunology project. Nat Rev Immunol. 2012;12(3):191\u2013200.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4703_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559.","journal-title":"PLoS ONE"},{"issue":"5","key":"4703_CR53","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/sctm.20-0472","volume":"10","author":"G Lanzoni","year":"2021","unstructured":"Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660\u201373.","journal-title":"Stem Cells Transl Med"},{"key":"4703_CR54","doi-asserted-by":"publisher","first-page":"1400533","DOI":"10.3389\/fimmu.2024.1400533","volume":"15","author":"I Kerkis","year":"2024","unstructured":"Kerkis I, da Silva AP, Araldi RP. The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions. Front Immunol. 2024;15:1400533.","journal-title":"Front Immunol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04703-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:04:47Z","timestamp":1762254287000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04703-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4703"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04703-w","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol \u201c\n                      Estudo First in Human para Avalia\u00e7\u00e3o da Seguran\u00e7a do Produto Investigacional Cellavita HD ap\u00f3s Aplica\u00e7\u00e3o Intravenosa em Participantes com Doen\u00e7a de Huntington\n                      \u201d was first approved by the Ethics Committee of\n                      Faculdade de Medicina de Jundiai\n                      (Approval number: 51005115.9.0000.5412) on December 11, 2015, conformed to the ICH-GCP guidelines. The last amendment was approved on November 7, 2019. All participants provided written informed consent before recruitment. This study was registered on ClinicalTrials.gov. Gov (Identifier: NCT02728115).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The investigational product evaluated in this study was originally developed under the name Cellavita HD. In March 2020, it was registered under the trademark NestaCell\u00ae. Both names refer to the same cell-based product. In this manuscript, the current designation NestaCell\u00ae is used consistently; however, the original name Cellavita HD is retained when citing regulatory documents\u2014such as the ethics committee approval\u2014where that designation was originally employed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clarification"}},{"value":"Written informed consent was obtained from all patients, all authors, and the Sponsor for the publication of this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EP & CVW are employees of the study sponsor. IK & CVW are listed as inventors on the NestaCell\u00ae patent and hold associated commercial rights. JMSF, LF & LHY declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"611"}}